EureKING hopes to help develop and manufacture novel cell and gene therapies and live biotherapeutics, among other types of biologics, through a number of strategic acquisitions.
The first European special-purpose acquisition company (SPAC) in the healthcare industry dedicated to bioproduction was launched today and hopes to become a leading CDMO in the region.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.
The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
